NPRO Napro Biotherapeutics (MM)

NaPro Announces Additions to Scientific Advisory Board BOULDER, Colo., Jan. 12 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc. today announced the following new appointments to its Scientific Advisory Board: Paul A Bunn, Jr., M.D.: Dr. Bunn is currently the Director of the University of Colorado Cancer Center, past president (2002-2003) of the American Society of Clinical Oncology (ASCO), and former chairman of the Oncology Drugs Advisory Committee (ODAC). Dr. Bunn is an authority in the field of clinical oncology with a research specialty in lung cancer. Dr. Bunn received his M.D. from Cornell University Medical Center. Theodore Friedmann, M.D.: Dr. Friedmann is a Professor of Pediatrics and Director of the Gene Therapy Program at the University of California, San Diego. Since 2000, he has served as the Chairman of the Recombinant DNA Advisory Committee (RAC) at the National Institutes of Health. Dr. Friedmann has over 40 years of research experience in the areas of genetics and molecular therapies. He received his M.D. from the University of Pennsylvania. Susan J. Gross, M.D.: Dr. Gross is the Co-Director of the Division of Reproductive Genetics at Montefiore Medical Center and Albert Einstein College of Medicine and an associate professor in Obstetrics, Gynecology and Pediatrics. Dr. Gross performs research and provides genetic counseling for women with hereditary cancer and those at high risk for genetic birth defects. She is board certified in obstetrics and gynecology and medical genetics. Dr. Gross received her M.D. from the University of Toronto. Stephen S. Morse, Ph.D.: Dr. Morse is Director of the Center for Public Health and Associate Professor of Clinical Epidemiology at Columbia University's Mailman School of Public Health. He is an expert in the epidemiology of emerging infections, international cooperation for infectious disease surveillance, and defense against bioterrorism. Dr. Morse spent four years in government service as Program Manager at the Defense Advanced Research Projects Agency (DARPA), Department of Defense, where he co-directed the Pathogen Countermeasures program and subsequently directed the Advanced Diagnostics program there. He holds a Ph.D. in Virology from the University of Wisconsin. "We are pleased to welcome these eminent scientists to our Scientific Advisory Board," stated Robert E. Pollack, Ph.D., Chairman of the NaPro Scientific Advisory Board. "These distinguished experts will expand the Board's collective expertise in NaPro's core research and development areas and help us guide the Company's strategy to bring forward promising new therapies in the field of oncology and the treatment of hereditary disease." Other members of NaPro's Scientific Advisory Board are: Robert E Pollack, Ph.D. (Chairman) Professor of Biological Sciences & Director, Center for the Study of Science and Religion, Columbia University Anthony J. Lechich, M.D., Senior Vice President of Medical Affairs and Medical Director, Terence Cardinal Cooke Health Care Center Malcolm A. S. Moore, D. Phil., Enid A Haupt Professor of Cell Biology & Head, James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan-Kettering Cancer Center Seth A. Rudnick, M.D., Managing Partner, Canaan Partners LLP Ethan Signer, Ph.D., Executive Director, High Q Foundation, Professor of Biology Emeritus, Massachusetts Institute of Technology Nancy S. Wexler, Ph.D., Higgins Professor of Neuropsychology, Columbia University About NaPro BioTherapeutics NaPro BioTherapeutics, Inc. is a life science company focused on the development of therapies for the targeted treatment of cancer and hereditary disease. For more information about NaPro and its technologies, visit NaPro's web site at http://www.naprobio.com/ . Forward Looking Statements The statements in this news release that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release, based on currently available information. Forward-looking statements can be identified by the use of words such as "believes," "intends," "estimates," "may," "will," "should," "anticipated," "expected" or comparable terminology or by discussions of strategy. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties including: risks associated with development of therapies in the field of oncology and the treatment of hereditary disease, and all of those factors identified under the captions "Risk Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary Note Regarding Forward Looking Statements" in the Company's documents filed from time to time with the SEC, including the Company's registration statement on Form S-3, as amended, dated August 8, 2003, its Annual Report on Forms 10-K and 10-K/A for the year ending December 31, 2002 filed with the SEC on March 27, April 30, August 8 and October 24, 2003, and its Quarterly Report on Form 10-Q for the quarter ended October 1, 2003 filed with the Securities and Exchange Commission on November 14, 2003. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those forecasted or expected. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise. For further information, please contact L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715; or investors, Lilian Stern of Stern Investor Relations, +1-212-362-1200; or media, Peter Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc. Web site: http://www.naprobio.com/

Copyright